BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, a Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-05-31
- Last Posted Date
- 2015-01-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 2457
- Registration Number
- NCT00332020
Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-05-25
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 4541
- Registration Number
- NCT00329628
Effect of Aprotinin on Transfusion Requirements in Patients Undergoing Elective Spinal Fusion Surgery
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2006-05-18
- Last Posted Date
- 2019-06-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 54
- Registration Number
- NCT00327379
ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer
- First Posted Date
- 2006-05-12
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 45
- Registration Number
- NCT00325351
Impact of SH T00658ID as Compared to a Monophasic Contraceptive Containing Ethinylestradiol and Levonorgestrel (SH D01155E) on Hemostatic Parameters
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2013-11-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 29
- Registration Number
- NCT00318799
- Locations
- 🇳🇱
Dinox B.V., Groningen, Netherlands
Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-04-25
- Last Posted Date
- 2013-10-21
- Lead Sponsor
- Bayer
- Target Recruit Count
- 220
- Registration Number
- NCT00317941
Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2015-12-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 65
- Registration Number
- NCT00313248
Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)
Phase 3
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2015-03-10
- Lead Sponsor
- Bayer
- Registration Number
- NCT00313976
Magnevist® Injection-enhanced MRA Compared to Non Contrast MRA for the Detection of Stenosis of the Renal Arteries
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-04-04
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 116
- Registration Number
- NCT00310557
Depiction of Delayed Enhancement in Patients With Documented Myocardial Infarction
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-04-04
- Last Posted Date
- 2014-12-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 73
- Registration Number
- NCT00310544
© Copyright 2024. All Rights Reserved by MedPath